Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Cambridge-based pharmaceutical company Generation Bio Co . has been notified by Nasdaq that it is at risk of being delisted from the Nasdaq Global Select Market. The company, which trades under the ticker (NASDAQ:GBIO), received a notice on Monday stating that its stock price had been below the required $1.00 minimum bid price for 30 consecutive business days. Currently trading at $0.58, the stock has experienced a significant decline of nearly 80% over the past six months, according to InvestingPro data.
The notice does not immediately affect the company’s listing, as it will continue to trade on the Nasdaq while it seeks to regain compliance with the exchange’s requirements. Generation Bio has until August 25, 2025, to lift its share price above $1.00 for at least 10 consecutive business days. If it fails to do so, it may be granted an additional 180-day grace period if it meets certain conditions and transfers its stock to the Nasdaq Capital Market. InvestingPro analysis indicates the company maintains a strong current ratio of 6.34, with more cash than debt on its balance sheet, though it’s currently rated as having WEAK overall financial health.
In the event that Generation Bio does not regain compliance within this timeframe, it could be delisted from Nasdaq, but would have the opportunity to appeal the decision. The company has expressed its intention to monitor its share price closely and explore options to satisfy the Nasdaq’s requirements. However, there is no guarantee that the company will be able to resolve the issue and maintain its listing.
This development is significant for investors and stakeholders of Generation Bio, as a delisting could impact the stock’s liquidity and market perception. The information is based on a press release statement from the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.